[关键词]
[摘要]
目的 系统评价痹祺胶囊治疗类风湿关节炎(rheumatoid arthritis,RA)的临床疗效与安全性,为临床合理用药提供循证医学证据。方法 计算机检索中国知网(CNKI)、万方数据知识服务平台(Wanfang Data)、维普数据库(VIP)、中国临床试验注册中心(CHiCTR)、国际传统医学临床试验注册平台(ITMCTR)、PubMed及Web of Science,检索时限为各数据库建库至2026年7月1日。中文检索策略为(“痹祺胶囊”OR”痹祺”)AND(“类风湿”OR”类风湿关节炎”OR”类风湿性关节炎”),英文检索策略为(“biqi”OR“BiQi Jiaonang”OR“BiQi capsules”)AND(“arthritis,rheumatoid”OR“rheumatoid arthritis”OR“RA”)。纳入痹祺胶囊治疗RA的随机对照试验(randomized controlled trial,RCT),由2名研究者独立筛选文献、提取数据并进行质量评价,采用RevMan 5.4软件进行Meta分析。结果 共纳入25项RCTs,涉及2 478例RA患者。Meta分析结果显示,(1)临床总有效率:痹祺胶囊治疗RA可显著提高总有效率 [RR=0.81,95% CI(0.78,0.85),P<0.000 01];(2)红细胞沉降率(erythrocyte sedimentation rate,ESR):痹祺胶囊可显著降低RA患者ESR [SMD=0.80,95% CI(0.32,1.28),P=0.001];(3)C反应蛋白(C-reactive protein,CRP):痹祺胶囊可显著降低RA患者CRP水平 [SMD=0.46,95% CI(0.03,0.89),P=0.03];(4)类风湿因子(rheumatoid factor,RF):痹祺胶囊可显著降低RA患者RF [SMD=0.53,95% CI(0.21,0.85),P=0.001];(5)DAS28评分:痹祺胶囊可显著降低RA患者DAS28评分 [SMD=0.42,95% CI(0.12,0.72),P=0.007];(6)晨僵时间:痹祺胶囊能显著减少RA患者晨僵时间 [SMD=0.35,95% CI(0.23,0.48),P<0.000 01];(7)不良反应发生率:痹祺胶囊治疗RA能显著减少不良反应发生率 [RR=0.52,95% CI(0.39,0.69),P<0.000 01]。1项RCT显示,痹祺胶囊可显著降低抗环瓜氨酸肽抗体(anti-cyclic citrullinated peptide antibody,anti-CCP)水平,且明显优于对照组(P<0.05)结论 痹祺胶囊治疗RA具有确切的临床疗效,可显著提高总有效率,改善ESR、CRP、RF等实验室指标及相关临床症状,且安全性良好。受纳入研究数量和质量限制,上述结论尚需更多高质量、大样本、多中心的RCT加以验证。
[Key word]
[Abstract]
Objective To systematically evaluate the clinical efficacy and safety of Biqi Capsule (痹祺胶囊) in the treatment of rheumatoid arthritis (RA), and provide evidence-based medical evidence for clinical rational drug use. Methods CNKI, Wanfang Data, VIP, Chinese Clinical Trial Registry (CHiCTR), International Traditional Medicine Clinical Trials Registry (ITMCTR), PubMed and Web of Science were searched by computer, and the search time limit was from the establishment of each database to July 1, 2026. The Chinese search strategy was (“biqi capsule” OR “biqi”) AND (“rheumatoid” OR “rheumatoid arthritis” OR “rheumatoid arthritis”), the English search strategy was (“biqi” OR “BiQi Jiaonang” OR “BiQi capsules”) AND (“arthritis, rheumatoid arthritis ” OR “RA”). Included in the randomized controlled trial (RCT) of Biqi Capsule for RA, two researchers independently screened the literature, extracted data and evaluated them, and the RevMan 5.4 software was used for Meta-analysis. Results A total of 25 RCTs were included, involving 2 478 patients with RA. Meta-analysis results showed: (1) Clinical total effective rate: Biqi Capsule treatment of RA could improve the total effective rate [RR = 0.81, 95% CI (0.78, 0.85), P < 0.000 01]; (2) Erythrocyte sedimentation rate (ESR): Biqi Capsule can significantly reduce the ESR of RA patients [SMD = 0.80, 95% CI (0.32, 1.28), P = 0.001]; (3) C-reactive protein (CRP): Biqi Capsule can significantly reduce the CRP of RA patients [SMD = 0.46, 95% CI (0.03, 0.89), P = 0.03]; (4) Rheumatoid factor (RF): Biqi Capsule could significantly reduce the RF of RA patients [SMD = 0.53, 95% CI (0.21, 0.85), P = 0.001]; (5) DAS28 score: Biqi Capsule could significantly reduce the DAS28 score of RA patients [SMD = 0.42, 95% CI (0.12, 0.72), P = 0.007]; (6) Morning stiffness time: Biqi Capsule could significantly reduce the morning stiffness time of RA patients [SMD = 0.35, 95% CI (0.23, 0.48), P < 0.000 01]; (7) Incidence of adverse reactions: Biqi Capsule treatment of RA had a significant decrease in incidence of adverse reactions [RR=0.52, 95% CI (0.39, 0.69), P<0.000 01]. One RCT showed that Biqi Capsules could significantly reduce the level of anti-cyclic citrullinated peptide antibody (anti-CCP), and was significantly better than the control group (P < 0.05). Conclusion Biqi Capsule has definite clinical efficacy in treating RA, it can significantly increase the total effective rate, improve ESR, CRP, RF and other laboratory indicators and related clinical symptoms, and has good safety. Due to the number and limitations of included studies, the above conclusions need to be verified by more high quality, large-sample and multi-center RCT.
[中图分类号]
R285
[基金项目]
国家自然科学基金项目(U23A6012); 中医证候全国重点实验室人员项目(QZ2025ZZ23); 广东省中医证候临床研究重点实验室(2023B1212060063); 广东省中医院横向课题(KYHT2025-2968,KYHT2025-1278)